Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02572817 · ClinicalTrials.gov registry record · Phase 3
Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A
A Phase 3 study of Influenza A Virus Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 138
- Enrollment target
- 20
- Study locations
NCT02572817: Completed Phase 3 study of Influenza A Virus Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT02572817 is a Phase 3 study of Influenza A Virus Infection that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 138 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02572817, a Phase 3 study of Influenza A Virus Infection, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 138 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study assessed the efficacy and safety of anti-influenza immune plasma, as an addition to standard of care antivirals, in participants hospitalized with severe influenza A infection.
Primary Outcome
The clinical status at Day 7 was based on a 6-point ordinal scale: 1. Death 2. In ICU 3. Non-ICU hospitalization, requiring supplemental oxygen (O2) 4. Non-ICU hospitalization, not requiring supplemental oxygen 5. Not hospitalized, but unable to resume normal activities 6. Not hospitalized with full resumption of normal activities A higher score corresponds to a better health outcome
Conditions Studied
Interventions
- BIOLOGICAL High-titer anti-influenza plasma
- BIOLOGICAL Low-titer anti-influenza plasma
Study Locations (20)
Massachusetts
- Massachusetts General Hospital - Boston
- Boston Children's Hospital - Boston
- University of Massachusetts Medical School - Worcester
Michigan
- University of Michigan - Ann Arbor
- Beaumont Hospital - Royal Oak - Royal Oak
- Beaumont Hospital, Troy - Troy
California
- UCLA Pediatrics Infectious Diseases - Los Angeles
- Naval Medical Center San Diego (NMCSD) - San Diego
Colorado
- Children's Hospital Colorado - Aurora
- University of Colorado Denver - Aurora
Maryland
- University of Maryland Medical Center - Baltimore
- Johns Hopkins University - Baltimore
Arizona
- University of Arizona Health Sciences Center - Tucson
Connecticut
- Bridgeport Hospital - Bridgeport
Florida
- University of Florida - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2015-11 |
| Est. Completion | 2018-05-18 |
| Phase | Phase 3 |
What the finished NCT02572817 record still lists
NCT02572817 is an interventional study that assigns participants to a tested intervention. The registered 138 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Influenza A Virus Infection appearing as the primary indexed condition, and to 2 interventions - of which High-titer anti-influenza plasma is the first listed.
NCT02572817 names 20 study sites across 13 states, led by Massachusetts, Michigan, California.
Frequently Asked Questions
What is clinical trial NCT02572817 about?
NCT02572817 is a clinical study titled "Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A". This study assessed the efficacy and safety of anti-influenza immune plasma, as an addition to standard of care antivirals, in participants hospitalized with severe influenza A infection.
What is the current status of trial NCT02572817?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 138 participants. The study started on 2015-11. Estimated completion is 2018-05-18.
What conditions does trial NCT02572817 study?
This clinical trial studies the following conditions: Influenza A Virus Infection.
What interventions are being tested in trial NCT02572817?
The interventions under investigation include: High-titer anti-influenza plasma (BIOLOGICAL), Low-titer anti-influenza plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT02572817?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02572817 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02572817's enrollment target sits among peer trials
138 1577th of 2000 higher than 421 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04402788 · 138 participants · Phase 2
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
- NCT04883255 · 138 participants · Early Phase 1
Cannabis Use, Cognition, and the Endocannabinoid System in HIV
- NCT05620784 · 138 participants · Phase 3
Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP
- NCT05832086 · 138 participants · Phase 2
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia